Efficacy and safety of rasagiline in Chinese patients with early Parkinson’s disease: a randomized, double-blind, parallel, placebo-controlled, fixed-dose study

Abstract Background Rasagiline is a monoamine oxidase-B inhibitor used for Parkinson’s disease (PD) treatment, but its effectiveness on Chinese patients is unclear. This study aimed to evaluate the efficacy and safety of rasagiline monotherapy in Chinese patients with early PD. Methods A 26-weeks, r...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Zhenxin Zhang, Jian Wang, Shengdi Chen, Chunfeng Liu, Baorong Zhang, Rong Peng, Shenggang Sun, Xiangru Sun, Gang Zhao, Qiumin Qu, Yansheng Li, Suiqiang Zhu, Xiaoping Pan, Ming Shao, Yanping Wang
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	BMC 2018-12-01
Edice:	Translational Neurodegeneration
Témata:	Parkinson’s disease Monoamine oxidase inhibitor Rasagiline Monotherapy China
On-line přístup:	http://link.springer.com/article/10.1186/s40035-018-0137-5
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!